熱門資訊> 正文
BioXcel重新遵守纳斯达克上市规则
2025-09-18 19:41
- BioXcel Therapeutics (NASDAQ:BTAI) has regained compliance with Nasdaq’s market value of listed securities (MVLS) requirement for continued listing on the exchange.
- On March 20, 2025, the company was notified by Nasdaq that it was not in compliance as its MVLS was below $35.0 million for 30 consecutive business days.
- Source: Press Release
More on BioXcel Therapeutics
- BioXcel Therapeutics, Inc. (BTAI) Discuses On SERENITY At-Home Pivotal Phase 3 Safety Trial Results Call (Transcript)
- BioXcel Therapeutics, Inc. (BTAI) Discuses On SERENITY At-Home Pivotal Phase 3 Safety Trial Results Call - Slideshow
- BioXcel whipsaws after late-stage trial win for lead asset
- Seeking Alpha’s Quant Rating on BioXcel Therapeutics
- Historical earnings data for BioXcel Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
